Azacitidine belongs to anti-cancer therapy of Oncology Division.

NA

Azashine is indicated for treatment of patients with the myelodysplastic syndrome subtypes: Refractory anemia or refractory anemia with ringed sideroblasts, Refractory anemia with excess blasts, in transformation, and chronic myelomonocytic leukemia.